{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:31:06Z","timestamp":1763458266702,"version":"3.44.0"},"publisher-location":"New York, NY, USA","reference-count":65,"publisher":"ACM","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dl.acm.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,13]]},"DOI":"10.1145\/3586139.3586154","type":"proceedings-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T18:23:21Z","timestamp":1691605401000},"page":"103-111","update-policy":"https:\/\/doi.org\/10.1145\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Investigating Conventional and Novel Methods for Treatment of Cancer"],"prefix":"10.1145","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1735-3552","authenticated-orcid":false,"given":"Zhixuan","family":"Qu","sequence":"first","affiliation":[{"name":"life science, Imperial College London, UK"}]}],"member":"320","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"e_1_3_2_1_1_1","unstructured":"Ochoa A. n.d.\u00a0Mechanisms of tumour escape from the immune response."},{"key":"e_1_3_2_1_2_1","doi-asserted-by":"crossref","unstructured":"Nazarian R. and Jazirehi A. 2014. Epigenomics and targeted therapy in cancer.\u00a0Epigenomics 6(6) pp.571-575.","DOI":"10.2217\/epi.14.72"},{"key":"e_1_3_2_1_3_1","first-page":"1008","volume":"1","author":"Li Y.","unstructured":"Li, Y., Li, L. & Wang, G. (2016) The present situation and trend of cancer nursing research. PLA Nursing Journal. 10.3969\/j.issn.1008-9993.","journal-title":"PLA Nursing Journal."},{"key":"e_1_3_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27992"},{"key":"e_1_3_2_1_5_1","first-page":"6","volume-title":"Theranostics: A treasured tailor for tomorrow.\u00a0Journal of Pharmacy and Bioallied Sciences, 6(5)","author":"Jeelani S.","year":"2014","unstructured":"Jeelani, S., Jagat Reddy, R., Maheswaran, T., Asokan, G., Dany, A. and Anand, B., 2014. Theranostics: A treasured tailor for tomorrow.\u00a0Journal of Pharmacy and Bioallied Sciences, 6(5), p.6."},{"key":"e_1_3_2_1_6_1","doi-asserted-by":"crossref","unstructured":"Shah J. Gonda A. Pemmaraju R. Subash A. Bobadilla Mendez C. Berger M. Zhao X. He S. Riman R. Tan M. Pierce M. Moghe P. and Ganapathy V. 2020. Shortwave Infrared-Emitting Theranostics for Breast Cancer Therapy Response Monitoring.\u00a0Frontiers in Molecular Biosciences 7.","DOI":"10.3389\/fmolb.2020.569415"},{"key":"e_1_3_2_1_7_1","doi-asserted-by":"crossref","unstructured":"Li D. Li D. Song G. Liang D. Chen C. Zhang Y. Gao Z. and He Y. 2018. Cancer survival in Cixian of China 2003-2013: a population-based study.\u00a0Cancer Medicine 7(4) pp.1537-1545.","DOI":"10.1002\/cam4.1416"},{"key":"e_1_3_2_1_8_1","volume-title":"Sarah Ludwig Rausch, &Kenna Simmons(2019)Retrieved","author":"Sandy McDowell","year":"2022","unstructured":"Sandy McDowell, Sarah Ludwig Rausch, &Kenna Simmons(2019)Retrieved January 26, 2022 from https:\/\/www.cancer.org\/latest-news\/cancer-research-insights-from-the-latest-decade-2010-to-2020.html"},{"key":"e_1_3_2_1_9_1","unstructured":"Kufe D. Holland J. and Frei E. 2003.\u00a0Cancer medicine 6. Hamilton Ont.: BC Decker."},{"key":"e_1_3_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1536"},{"key":"e_1_3_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318292e4e3"},{"key":"e_1_3_2_1_12_1","volume-title":"Philadelphia: Wolters Kluwer.","author":"Skeel R.","year":"2015","unstructured":"Skeel, R. and Khlief, S., 2015.\u00a0Handbook of Cancer Chemotherapy. Philadelphia: Wolters Kluwer."},{"key":"e_1_3_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0b013e3181b4adb5"},{"key":"e_1_3_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.4236\/jct.2014.58089"},{"key":"e_1_3_2_1_15_1","unstructured":"Mayles P. Nahum A. and Rosenwald J. n.d.\u00a0Handbook of radiotherapy physics."},{"key":"e_1_3_2_1_16_1","doi-asserted-by":"crossref","unstructured":"Joiner M. and Van Der Kogel A. 2009.\u00a0Basic clinical radiobiology. London: Edward Arnold.","DOI":"10.1201\/b15450"},{"key":"e_1_3_2_1_17_1","doi-asserted-by":"crossref","unstructured":"Chen H. and Kuo M. 2017. Improving radiotherapy in cancer treatment: Promises and challenges.\u00a0Oncotarget 8(37) pp.62742-62758.","DOI":"10.18632\/oncotarget.18409"},{"key":"e_1_3_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2011.12.002"},{"key":"e_1_3_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-013-1034-z"},{"key":"e_1_3_2_1_20_1","first-page":"311","volume-title":"Cardiac side effects of conventional and particle radiotherapy in cancer patients.\u00a0Herz, 36(4)","author":"Wittig A.","unstructured":"Wittig, A. and Engenhart-Cabillic, R., 2011. Cardiac side effects of conventional and particle radiotherapy in cancer patients.\u00a0Herz, 36(4), pp.311-324."},{"key":"e_1_3_2_1_21_1","first-page":"203","volume-title":"The role of radiotherapy in lung cancer: Where is the evidence?\u00a0Radiotherapy and Oncology, 83(2)","author":"Jassem J.","unstructured":"Jassem, J., 2007. The role of radiotherapy in lung cancer: Where is the evidence?\u00a0Radiotherapy and Oncology, 83(2), pp.203-213."},{"key":"e_1_3_2_1_22_1","first-page":"9","volume-title":"Breakthrough Status to Pancreatic Cancer Immunotherapy. 36(16)","author":"Oncology Times","unstructured":"Oncology Times, 2014. Breakthrough Status to Pancreatic Cancer Immunotherapy. 36(16), p.9."},{"key":"e_1_3_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5"},{"key":"e_1_3_2_1_24_1","doi-asserted-by":"crossref","unstructured":"Fife B. and Bluestone J. 2008. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.\u00a0Immunological Reviews 224(1) pp.166-182.","DOI":"10.1111\/j.1600-065X.2008.00662.x"},{"key":"e_1_3_2_1_25_1","volume":"23","author":"Twomey J.","unstructured":"Twomey, J. and Zhang, B., 2021. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.\u00a0The AAPS Journal, 23(2).","journal-title":"The AAPS Journal"},{"key":"e_1_3_2_1_26_1","volume-title":"Retrieved","author":"U.S. Food and Drug Administration","year":"2022","unstructured":"U.S. Food and Drug Administration. 2022.\u00a0New Drug Therapy Approvals 2020. Retrieved January 26, 2022 from https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/new-drug-therapy-approvals-2020"},{"issue":"1","key":"e_1_3_2_1_27_1","first-page":"84","volume":"143","author":"Tang Y.","unstructured":"Tang, Y., Xu, X., Song, H., Yang, S., Shi, S., Wei, J., Pan, B., Zhao, F., Liao, C. and Luo, C., 2008. Early diagnostic and prognostic significance of a specific Th1\/Th2 cytokine pattern in children with haemophagocytic syndrome.\u00a0British Journal of Haematology, 143(1), pp.84-91.","journal-title":"Haematology"},{"key":"e_1_3_2_1_28_1","doi-asserted-by":"crossref","unstructured":"Morse M. Clay T. and Lyerly H. 2002. Current status of adoptive immunotherapy of malignancies.\u00a0Expert Opinion on Biological Therapy 2(3) pp.237-247.","DOI":"10.1517\/14712598.2.3.237"},{"key":"e_1_3_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3930"},{"key":"e_1_3_2_1_30_1","doi-asserted-by":"crossref","unstructured":"Holzl\u00f6hner P. and Hanack K. 2017. Generation of Murine Monoclonal Antibodies by Hybridoma Technology.\u00a0Journal of Visualized Experiments (119).","DOI":"10.3791\/54832-v"},{"key":"e_1_3_2_1_31_1","first-page":"15","volume-title":"Hybridoma technology. \u00a0ELISA","author":"Hnasko R. M.","unstructured":"Hnasko, R. M., & Stanker, L. H., 2015. Hybridoma technology. \u00a0ELISA. pp. 15-28."},{"key":"e_1_3_2_1_32_1","doi-asserted-by":"crossref","unstructured":"Zahavi D. and Weiner L. 2020. Monoclonal Antibodies in Cancer Therapy.\u00a0Antibodies 9(3) p.34.","DOI":"10.3390\/antib9030034"},{"volume-title":"J., Pluzanski, A., Arrieta, O., Frontera, O., Chiari, R., Butts, C., Wojcik-Tomaszewska, J., Coudert, B., Garassino, M., Ready, N., Felip, E., Garcia, M.","author":"Gettinger S.","key":"e_1_3_2_1_33_1","unstructured":"Gettinger, S., Borghaei, H., Brahmer, J., Chow, L., Burgio, M., De Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O., Chiari, R., Butts, C., Wojcik-Tomaszewska, J., Coudert, B., Garassino, M., Ready, N., Felip, E., Garcia, M., Waterhouse, D., Domine, M., Barlesi, F., Antonia, S., Wohlleber, M., Gerber, D., Czyzewicz, G., Spigel, D., Crino, L., Eberhardt, W., Li, A., Marimuthu, S. and Vokes, E., 2019. OA14.04 Five-Year Outcomes from the Randomized, Phase 3 Trials CheckMate 017\/057: Nivolumab vs Docetaxel in Previously Treated NSCLC.\u00a0Journal of Thoracic Oncology, 14(10), pp.S244-S245."},{"key":"e_1_3_2_1_34_1","volume-title":"Mechanistic considerations for the use of monoclonal antibodies for cancer therapy[J]. Cancer biology & medicine","author":"Glassman P. M.","year":"2014","unstructured":"Glassman P. M., and Balthasar. J. P., 2014. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy[J]. Cancer biology & medicine, 2014, 11(1): 20."},{"key":"e_1_3_2_1_35_1","doi-asserted-by":"crossref","unstructured":"Melero I. Hervas-Stubbs S. Glennie M. Pardoll D. and Chen L. 2007. Immunostimulatory monoclonal antibodies for cancer therapy.\u00a0Nature Reviews Cancer 7(2) pp.95-106.","DOI":"10.1038\/nrc2051"},{"key":"e_1_3_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.01.007"},{"key":"e_1_3_2_1_37_1","doi-asserted-by":"crossref","unstructured":"Zhang Z. Liu S. Zhang B. Qiao L. Zhang Y. and Zhang Y. 2020. T Cell Dysfunction and Exhaustion in Cancer.\u00a0Frontiers in Cell and Developmental Biology 8.","DOI":"10.3389\/fcell.2020.00017"},{"key":"e_1_3_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5"},{"issue":"16","key":"e_1_3_2_1_39_1","first-page":"1509","volume":"368","author":"June C.","unstructured":"June, C., 2013. Chimeric Antigen Receptor\u2013Modified T Cells for Acute Lymphoid Leukemia.\u00a0New England Journal of Medicine, 368(16), pp.1509-1518.","journal-title":"Medicine"},{"key":"e_1_3_2_1_40_1","doi-asserted-by":"crossref","unstructured":"Hartmann J. Sch\u00fc\u00dfler\u2010Lenz M. Bondanza A. and Buchholz C. 2017. Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts.\u00a0EMBO Molecular Medicine 9(9) pp.1183-1197.","DOI":"10.15252\/emmm.201607485"},{"key":"e_1_3_2_1_41_1","volume-title":"Retrieved","author":"England N.","year":"2022","unstructured":"England, N., 2022.\u00a0NHS England \u00bb CAR-T Therapy. [online] England.nhs.uk. Retrieved January 26, 2022 from https:\/\/www.england.nhs.uk\/cancer\/cdf\/car-t-therapy\/."},{"key":"e_1_3_2_1_42_1","doi-asserted-by":"crossref","unstructured":"Shah N. and Fry T. 2019. Mechanisms of resistance to CAR T cell therapy.\u00a0Nature Reviews Clinical Oncology.","DOI":"10.1038\/s41571-019-0184-6"},{"key":"e_1_3_2_1_43_1","volume-title":"Retrieved","author":"Cancerresearchuk","year":"2022","unstructured":"Cancerresearchuk.org. 2022.\u00a0CAR T-cell therapy | Cancer Research UK. Retrieved January 26, 2022 from https:\/\/www.cancerresearchuk.org\/about-cancer\/cancer-in-general\/treatment\/immunotherapy\/types\/CAR-T-cell-therapy"},{"key":"e_1_3_2_1_44_1","unstructured":"Grupp S. Kalos M. Barrett D. Aplenc R. Porter D. Rheingold S. Teachey D. Chew A. Hauck B. Wright J. Milone M. Levine B. and"},{"issue":"1","key":"e_1_3_2_1_45_1","first-page":"43","volume":"26","author":"Barrett D.","unstructured":"Barrett, D., Teachey, D. and Grupp, S., 2014. Toxicity management for patients receiving novel T-cell engaging therapies.\u00a0Current Opinion in Pediatrics, 26(1), pp.43-49.","journal-title":"Pediatrics"},{"key":"e_1_3_2_1_46_1","doi-asserted-by":"crossref","unstructured":"Gust J. Hay K. Hanafi L. Li D. Myerson D. Gonzalez-Cuyar L. Yeung C. Liles W. Wurfel M. Lopez J. Chen J. Chung D. Harju-Baker S. \u00d6zpolat T. Fink K. Riddell S. Maloney D. and Turtle C. 2017. Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.\u00a0Cancer Discovery 7(12) pp.1404-1419.","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_3_2_1_47_1","unstructured":"NobelPrize.org. 2022.\u00a0The Nobel Prize in Chemistry 2020. Retrieved February 4 2022 from https:\/\/www.nobelprize.org\/prizes\/chemistry\/2020\/press-release\/"},{"key":"e_1_3_2_1_48_1","doi-asserted-by":"crossref","unstructured":"Uddin F. Rudin C. and Sen T. 2020. CRISPR Gene Therapy: Applications Limitations and Implications for the Future.\u00a0Frontiers in Oncology 10.","DOI":"10.3389\/fonc.2020.01387"},{"key":"e_1_3_2_1_49_1","first-page":"349","volume-title":"CRISPR Crossroads for Genome Editing.\u00a0The CRISPR Journal, 1(6)","author":"Barrangou R.","unstructured":"Barrangou, R., 2018. CRISPR Crossroads for Genome Editing.\u00a0The CRISPR Journal, 1(6), pp.349-350."},{"key":"e_1_3_2_1_50_1","doi-asserted-by":"crossref","unstructured":"Jiang F. and Doudna J. 2017. CRISPR\u2013Cas9 Structures and Mechanisms.\u00a0Annual Review of Biophysics 46(1) pp.505-529.","DOI":"10.1146\/annurev-biophys-062215-010822"},{"key":"e_1_3_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3950"},{"key":"e_1_3_2_1_52_1","doi-asserted-by":"crossref","unstructured":"Symeonidi E. Regalado J. Schwab R. and Weigel D. 2021. CRISPR-finder: A high throughput and cost-effective method to identify successfully edited Arabidopsis thaliana individuals.\u00a0Quantitative Plant Biology 2.","DOI":"10.1017\/qpb.2020.6"},{"key":"e_1_3_2_1_53_1","doi-asserted-by":"crossref","unstructured":"Zhang H. Qin C. An C. Zheng X. Wen S. Chen W. Liu X. Lv Z. Yang P. Xu W. Gao W. and Wu Y. 2021. Application of the CRISPR\/Cas9-based gene editing technique in basic research diagnosis and therapy of cancer.\u00a0Molecular Cancer 20(1).","DOI":"10.1186\/s12943-021-01431-6"},{"key":"e_1_3_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam9321"},{"key":"e_1_3_2_1_55_1","first-page":"722","volume-title":"M., Mehta, A., Kothari, A., Wang, D., Visal, T., Li, M., Pinto, J., Castrillon, J., Cheney, E., Bouwman, P., Jonkers, J., Rottenberg, S., Guerriero, J., Wulf","author":"Pantelidou C.","year":"2019","unstructured":"Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A., Kothari, A., Wang, D., Visal, T., Li, M., Pinto, J., Castrillon, J., Cheney, E., Bouwman, P., Jonkers, J., Rottenberg, S., Guerriero, J., Wulf, G. and Shapiro, G., 2019. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.\u00a0Cancer Discovery, 9(6), pp.722-737."},{"key":"e_1_3_2_1_56_1","doi-asserted-by":"crossref","unstructured":"Zuckermann M. Hovestadt V. Knobbe-Thomsen C. Zapatka M. Northcott P. Schramm K. Belic J. Jones D. Tschida B. Moriarity B. Largaespada D. Roussel M. Korshunov A. Reifenberger G. Pfister S. Lichter P. Kawauchi D. and Gronych J. 2015. Somatic CRISPR\/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling.\u00a0Nature Communications 6(1).","DOI":"10.1038\/ncomms8391"},{"key":"e_1_3_2_1_57_1","doi-asserted-by":"crossref","unstructured":"Moses C. Nugent F. Waryah C. Garcia-Bloj B. Harvey A. and Blancafort P. 2019. Activating PTEN Tumor Suppressor Expression with the CRISPR\/dCas9 System.\u00a0Molecular Therapy - Nucleic Acids 14 pp.287-300.","DOI":"10.1016\/j.omtn.2018.12.003"},{"key":"e_1_3_2_1_58_1","doi-asserted-by":"crossref","unstructured":"Mansoori B. Mohammadi A. Davudian S. Shirjang S. and Baradaran B. 2017. The Different Mechanisms of Cancer Drug Resistance: A Brief Review.\u00a0Advanced Pharmaceutical Bulletin 7(3) pp.339-348.","DOI":"10.15171\/apb.2017.041"},{"key":"e_1_3_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/1724600817753098"},{"key":"e_1_3_2_1_60_1","doi-asserted-by":"crossref","unstructured":"Modrzejewski D. Hartung F. Lehnert H. Sprink T. Kohl C. Keilwagen J. and Wilhelm R. 2020. Which Factors Affect the Occurrence of Off-Target Effects Caused by the Use of CRISPR\/Cas: A Systematic Review in Plants.\u00a0Frontiers in Plant Science 11.","DOI":"10.3389\/fpls.2020.574959"},{"key":"e_1_3_2_1_61_1","doi-asserted-by":"crossref","unstructured":"Haapaniemi E. Botla S. Persson J. Schmierer B. and Taipale J. 2018. CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response.\u00a0Nature Medicine 24(7) pp.927-930.","DOI":"10.1038\/s41591-018-0049-z"},{"key":"e_1_3_2_1_62_1","doi-asserted-by":"crossref","unstructured":"Biswas P. Anand U. Ghorai M. Pandey D. Jha N. Behl T. Kumar M. Kumar R. Shekhawat M. and Dey A. 2021. Unravelling the promise and limitations of CRISPR\/Cas system in natural product research: Approaches and challenges.\u00a0Biotechnology Journal p.2100507.","DOI":"10.1002\/biot.202100507"},{"key":"e_1_3_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4681"},{"key":"e_1_3_2_1_64_1","unstructured":"MIT Technology Review. 2022.\u00a0Top U.S. Intelligence Official Calls Gene Editing a WMD Threat. Retrieved February 4 2022 from https:\/\/www.technologyreview.com\/2016\/02\/09\/71575\/top-us-intelligence-official-calls-gene-editing-a-wmd-threat\/"},{"key":"e_1_3_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2016-0010"}],"event":{"name":"ICBBB 2023: 12th International Conference on Bioscience, Biochemistry and Bioinformatics","acronym":"ICBBB 2023","location":"Tokyo Japan"},"container-title":["Proceedings of the 12th International Conference on Bioscience Biochemistry and Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3586139.3586154","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dl.acm.org\/doi\/pdf\/10.1145\/3586139.3586154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T19:10:56Z","timestamp":1755889856000},"score":1,"resource":{"primary":{"URL":"https:\/\/dl.acm.org\/doi\/10.1145\/3586139.3586154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":65,"alternative-id":["10.1145\/3586139.3586154","10.1145\/3586139"],"URL":"https:\/\/doi.org\/10.1145\/3586139.3586154","relation":{},"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"2023-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}